Elsevier

Life Sciences

Volume 57, Issue 23, 27 October 1995, Pages 2113-2125
Life Sciences

Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding

https://doi.org/10.1016/0024-3205(95)02204-VGet rights and content

Abstract

In order to quantitate the extent to which opioid agonist potencies obtained in behavioral assays are determined by the apparent in vivo affinity and efficacy of the agonist, the antinociceptive effects of the mu opioid agonists morphine, fentanyl, etonitazene, and NIH 10741 were assessed before and after administration of the insurmountable mu opioid antagonist clocinnamox (CCAM) in a 55 °C warm-water tail withdrawal test in Swiss albino mice. Under control conditions, all four mu opioid agonists produced a full antinociceptive response with the following ED50 values (in mg/kg): morphine, 12; fentanyl, 0.47; etonitazene, 0.039; NIH 10741, 0.0051. Analysis of CCAM's effects according to Black and Leff gave the following agonist efficacy or tau values: Morphine, 4; fentanyl 15, etonitazene, 7; and NIH 10741, 59. The respective ka values were (in mg/kg): morphine, 29; fentanyl, 7.3; etonitazene, 0.22; and NIH 10741, 0.30. The major determinant of the experimentally observed ED50 values seemed to be the apparent in vivo affinity of the respective agonist and not its efficacy. ka values (expressed as mol/kg) correlated with the Ki values (in mol/1) obtained with [3H]DAMGO radioligand inding (r = 0.96 for pKA vs. pKi), although being on average 11,000-fold higher. Values for q, the available receptor fraction as determined in the behavioral experiments, correlated strongly (r = 0.96) with the q values determined by ex vivo [3H]DAMGO- and [3H]naltrexone equilibrium binding (i.e., Bmax,clocinnamox/Bmax,control), the relationship approaching unity.

References (25)

  • F. Porreca et al.

    Life Sci.

    (1982)
  • R.F. Furchgott

    Adv. Drug Res.

    (1966)
  • J.W. Black et al.

    Br. J. Pharmacol.

    (1985)
  • J.W. Black et al.
  • A.M. Young et al.
  • C.P. France et al.

    J Pharmacol Exp Ther

    (1984)
  • G. Winger et al.

    J. Pharmacol. Exp. Ther.

    (1992)
  • G. Zernig et al.

    J. Pharmacol. Exp. Ther.

    (1994)
  • J.W. Lewis et al.

    NIDA Res. Monogr.

    (1988)
  • G.A. Brine et al.

    Med. Chem. Res.

    (1992)
  • P.A.J. Janssen et al.

    Arzneim. Forsch./Drug Res.

    (1963)
  • S.D. Comer et al.

    J. Pharmacol. Exp. Ther.

    (1992)
  • Cited by (40)

    • Hydromorphone efficacy and treatment protocol impact on tolerance and μ-opioid receptor regulation

      2008, European Journal of Pharmacology
      Citation Excerpt :

      Regulation of μ-opioid receptor density is also related to analgesic efficacy, since higher efficacy agonists, but not lower efficacy agonists, are associated with μ-opioid receptor internalization and downregulation both in vivo and in vitro (Keith et al., 1996, 1998; Patel et al., 2002; Stafford et al., 2001; Yoburn et al., 2004; however see Haberstock-Debic et al., 2005). To date, quantitative estimates of analgesic efficacy (i.e., τ) have been confined to a relatively limited group of opioid agonists (e.g., Pawar et al., 2007; Pitts et al., 1998; Walker et al., 1998; Zernig et al., 1995). Furthermore, there are few studies directly examining the relationship between analgesic τ values, in vivo tolerance and μ-opioid receptor regulation (Pawar et al., 2007).

    View all citing articles on Scopus
    View full text